{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009480","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.957454+00:00","generated_at":"2026-06-17T19:15:41.104616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PepGen FY2022 net loss $69.1M, cash $181.8M; Phase 2 trials planned for 2023","bullets":["Net loss $14.9M in Q4 2022, $69.1M for full year 2022 (vs $27.3M in 2021).","Cash and cash equivalents $181.8M as of Dec 31, 2022; expected to fund operations into early 2025.","R&D expenses $54.1M in FY2022 (vs $19.0M in 2021) driven by PGN-EDO51 and PGN-EDODM1 programs.","Anticipates initiating CONNECT1-EDO51 (Phase 2 open-label) in H1 2023 and CONNECT2-EDO51 (randomized) in H2 2023.","Phase 1 FREEDOM-DM1 trial for myotonic dystrophy type 1 expected to start H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009480","json":"https://secwatch.observer/filing/0000950170-23-009480.json","markdown":"https://secwatch.observer/filing/0000950170-23-009480.md","text":"https://secwatch.observer/filing/0000950170-23-009480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/0000950170-23-009480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/pepg-20230323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T19:15:41.104616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a832d4435b40621cb6e95e7bcf3bbf064f01bd5","claim":"PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/0000950170-23-009480-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}